The "Spike Report" in the eyes of Spike
Release time:
2022-04-06
New Starting Point, Xiang Chongping
, Deputy General Manager of Growth
■ Group Company, was a long time ago. Inadvertently, the "Peak News" was founded on the 8th anniversary of 30. The 10th anniversary of 30# is not long, short is not short, but the past is not like smoke. It is very impressive to recall the past. "Peak newspaper" from scratch, from the green, thin, and gradually grow, and day by day to mature. Her growth also witnessed the development of the pinnacle business. Since its establishment,
"Peak Newspaper" has always taken enterprise operation, management and cultural construction as its own responsibilities in content."Peak Headline " has exerted its functions of unifying ideas, gathering strength and guiding development; "enterprise vertical and horizontal " timely reports the development achievements and the latest trends of the enterprise, "enterprise perspective " better shows the image of the group's enterprises, builds a bridge for the communication and exchange within the company, "furong " constructs the construction of enterprise culture, it is a window of corporate culture and employee life. In the form of pictures and texts, the preparation is exquisite, it is a standard enterprise newspaper.
After30 years of "Peak Newspaper", it records the brilliant achievements of peak people in keeping pace with the times and striving hard: the opening up of peak cement has enabled peak people to appreciate the bronze culture of Daye Huaxia bronze birthplace; In Pu 'er, the birthplace of the ancient tea-horse road, I smelled the mellow fragrance of tea. In Huang Ping of Qiandongnan Prefecture, I felt the civilization of Qiangguo. The intensive cultivation of Jianfeng Pharmaceutical Co., Ltd., from the R & D, production and operation of pharmaceutical and chemical intermediates and pharmaceutical raw materials; the R & D, production and operation of infant drugs; the construction of international first-class and domestic leading international production line of pharmaceutical preparations; the research and development of small molecule targeted tumor drugs, all contribute to the strength of human life and health. Other industries go hand in hand, adding a rich and colorful stroke to the peak business. The "Spike News" witnessed every footprint of the Spike Man on the way to climb; it also witnessed the struggle mark engraved on each milestone in the Spike Man's difficult journey. All of these, soaked in the pinnacle people pioneering and innovative, the pursuit of development under the hard sweat, but also carrying the vision and hope of all the pinnacle people. The 36th anniversary of "peak newspaper" 30# is also the 46th anniversary of peak people "unite and struggle , seek truth and innovation , aspire to rise to the top and climb to the top forever " . As a reader, I sincerely congratulate the 51st anniversary of the founding of "Peak News" 30. In the spring and autumn of 30
, the peak newspaper has won many honors and become a leader in the enterprise newspaper. These achievements are gratifying. However, today's advantages and achievements only represent the past. If we only maintain the existing vision, today's achievements may also become an obstacle to future development; if we are only satisfied with today, we will not be able to survive in the fickle tomorrow. We know that it may not be difficult to set up an enterprise newspaper, but it is not easy to persevere in running an enterprise newspaper.30 "Peak Report" embodies past achievements and heralds a new starting point. Under the background of the unpredictable international situation and the ups and downs of the economic situation, "The wise changes with the times, and the wise makes "
. I believe that the peak people will realize their dream of"Centennial Enterprise " with their unique wisdom and innovation. At the same time, I wish the "peak newspaper" to take this as a new starting point, grow together with the peak business, and do better and better in the next 30 !
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page